Erratum: Enterotypes of the human gut microbiome

Arumugam, Muthu; Raes, Jeroen; Pelletier, Éric; Paslier, Denis Le; Yamada, Takuji; Mende, Daniel; Fernandes, Gabriel R.; Tap, Julien; Brüls, Thomas; Batto, Jean Michel; Bertalan, Marcelo; Borruel, Natalia; Casellas, Francesc; Fernández, Leyden; Gautier, Laurent; Hansen, Torben; Hattori, Masahira; Hayashi, Tetsuya; Kleerebezem, Michiel; Kurokawa, Ken; Leclerc, Marion; Levenez, Florence; Manichanh, Chaysavanh; Nielsen, H. Bjã̧; Nielsen, Trine; Pons, Nicolas; Poulain, Julie; Qin, Junjie; Sicheritz-Pontén, Thomas; Tims, Sebastian; Torrents, David; Ugarte, Edgardo; Zoetendal, Erwin G.; Junwang,; Guarner, Francisco; Pedersen, Oluf; Vos, Willem M. de; Brunak, Søren; Dora, Joel; Weissenbach, Jean; Ehrlich, S. Dusko; Bork, Peer

doi:10.1038/nature10187

Cited by 237 publications

(270 citation statements)

References 1 publication

Supporting

Mentioning

234

Contrasting

Unclassified

Order By: Relevance

“…Studies in obese adults reported reduced diversity, an increase in Firmicutes and a corresponding decrease in Bacteroidetes, although this was not seen in all studies 4,6,43 .…”

Section: West 13mentioning

confidence: 75%

“…Established microbiota of adult humans can be divided into different "enterotypes" based on clusters of predominant bacterial genera in the gut microbiome 43 . As yet, it is not clear how these enterotypes are formed, but this process is likely to be influenced by diet and other environmental factors 4,43,44 . Recently, it has also been argued that there are gradients of key genera rather than distinct clusters 4,45,46 .…”

Section: West 11mentioning

confidence: 99%

See 1 more Smart Citation

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

West

Renz²,

Jenmalm

et al. 2015

Journal of Allergy and Clinical Immunology

222

165

View full text Add to dashboard Cite

Rapid environmental transition and modern lifestyles are likely driving changes in the biodiversity of the human gut microbiota. With clear effects on physiologic, immunologic, and metabolic processes in human health, aberrations in the gut microbiome and intestinal homeostasis have the capacity for multisystem effects. Changes in microbial composition are implicated in the increasing propensity for a broad range of inflammatory diseases, such as allergic disease, asthma, inflammatory bowel disease (IBD), obesity, and associated noncommunicable diseases (NCDs). There are also suggestive implications for neurodevelopment and mental health. These diverse multisystem influences have sparked interest in strategies that might favorably modulate the gut microbiota to reduce the risk of many NCDs. For example, specific prebiotics promote favorable intestinal colonization, and their fermented products have anti-inflammatory properties. Specific probiotics also have immunomodulatory and metabolic effects. However, when evaluated in clinical trials, the effects are variable, preliminary, or limited in magnitude. Fecal microbiota transplantation is another emerging therapy that regulates inflammation in experimental models. In human subjects it has been successfully used in cases of Clostridium difficile infection and IBD, although controlled trials are lacking for IBD. Here we discuss relationships between gut colonization and inflammatory NCDs and gut microbiota modulation strategies for their treatment and prevention

show abstract

“…Studies in obese adults reported reduced diversity, an increase in Firmicutes and a corresponding decrease in Bacteroidetes, although this was not seen in all studies 4,6,43 .…”

Section: West 13mentioning

confidence: 75%

Section: West 11mentioning

confidence: 99%

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

West

Renz²,

Jenmalm

et al. 2015

Journal of Allergy and Clinical Immunology

222

165

View full text Add to dashboard Cite

show abstract

“…dominated by Bacteroides, Prevotella or Ruminococcus). It had been postulated that each state may be prognostically and diagnostically predictive (33) , however the existence, and the number of distinct enterotype classifications has recently been questioned (34) .…”

Section: The Gastrointestinal Microbiotamentioning

confidence: 99%

Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet

Staudacher

Whelan

2016

Proc. Nutr. Soc.

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a functional bowel disorder characterised by abdominal pain or discomfort with disordered defecation. This review describes the role of the gastrointestinal (GI) microbiota in the pathogenesis of IBS and how dietary strategies to manage symptoms impact on the microbial community. Evidence suggests a dysbiosis of the luminal and mucosal colonic microbiota in IBS, frequently characterised by a reduction in species of Bifidobacteria which has been associated with worse symptom profile. Probiotic supplementation trials suggest intentional modulation of the GI microbiota may be effective in treating IBS. A smaller number of prebiotic supplementation studies have also demonstrated effectiveness in IBS whilst increasing Bifidobacteria. In contrast, a novel method of managing IBS symptoms is the restriction of short-chain fermentable carbohydrates (low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet). Studies consistently demonstrate clinical effectiveness of the low FODMAP diet in patients with IBS. However, one unintentional consequence of this dietary intervention is its impact on the microbiota. This leads to an interesting paradox; namely, increasing luminal Bifidobacteria through probiotic supplementation is associated with a reduction in IBS symptoms while in direct conflict to this, the low FODMAP diet has clinical efficacy but markedly reduces luminal Bifidobacteria concentration. Given the multifactorial aetiology of IBS, the heterogeneity of symptoms and the complex and diverse nature of the microbiome, it is probable that both interventions are effective in patient subgroups. However combination treatment has never been explored and as such, presents an exciting opportunity for optimising clinical management, whilst preventing potentially deleterious effects on the GI microbiota. Irritable bowel syndrome: Prebiotic: Probiotic: FODMAP Irritable bowel syndromeFunctional bowel disorders are characterised by chronic lower gastrointestinal (GI) symptoms in the absence of alarm features that suggest presence of other disease (1,2) . The criteria for irritable bowel syndrome (IBS), one of the most common functional bowel disorders, requires the presence of abdominal pain or discomfort together with an alteration in stool output (1) . IBS is a common condition worldwide, contributes up to 30 % of gastroenterology consultations in the UK (3) , affects more females than males and is more prevalent in those under 40 years of age (4) . A pooled prevalence of IBS in 14 % of females and 9 % of males has been reported in a large systematic review and meta-analysis of fifty-five studies conducted across America, Asia, Europe and Africa (4) .Four different IBS subtypes exist based on predominant stool form, and each may differ in their aetiology.

show abstract

“…1 While presence of Bacteroides correlates with high-fat high-protein consumption, Prevotella is linked to intake of fibers, simple sugars and carbohydrates.…”

Section: Gut Microbiota Inflammation and Hepatic Encephalopathy: A Pmentioning

confidence: 99%

Gut Microbiota, Inflammation and Hepatic Encephalopathy: A Puzzle with a Solution in Sight

Dhiman

2012

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

Erratum: Enterotypes of the human gut microbiome

Cited by 237 publications

References 1 publication

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet

Gut Microbiota, Inflammation and Hepatic Encephalopathy: A Puzzle with a Solution in Sight

Contact Info

Product

Resources

About